HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
March 26, 2024 Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LVDD Can Be Recommended Southlake, Texas, March 26, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a
View All HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes March 12, 2024 Data Demonstrated MyoVista AI-ECG model significantly
View All HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology
March 6, 2024 Southlake, TX, March 06, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused
Today Show highlights that AI-ECG is set to change medicine and save lives.
Excerpt from the Today Show. Watch the video using the following link: heartsciences.com/wp-content/uploads/2024/02/The-cutting-edge-way-doctors-are-using-AI-to-save-lives_1.mp4
How AI is Reshaping Diagnostic Tools
How AI is Reshaping Diagnostic Tools In healthcare, innovation saves lives. From the ECG discovery in 1895 to today’s AI breakthroughs, now AI is changing medicine. March 1, 2024
HeartSciences Appoints New Scientific Advisory Board Member
February 1, 2024 Southlake, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused